Public, NASDAQ:VICL
NASDAQ Global Market
Vical Reports 2011 Financial Results and Progress in Key Development Programs
Date: Wed, 08 Feb 2012 11:31:16 GMT
Tags:
Vical Reports 2011 Financial Results and Progress in Key Development Programs
MarketWatch (press release) - 20 minutes ago
MarketWatch (press release) - 20 minutes ago
SAN DIEGO, Feb 8, 2012 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/zigman/53362/quotes/nls/vicl VICL +0.53% today reported financial results for the year ended December 31, 2011.
Vical Announces News Release and Conference Call Schedule for 2011 Financial ...
Date: Thu, 02 Feb 2012 11:31:55 GMT
Tags:
Vical Announces News Release and Conference Call Schedule for 2011 Financial ...
MarketWatch (press release) - Feb 2, 2012
MarketWatch (press release) - Feb 2, 2012
SAN DIEGO, Feb 2, 2012 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/zigman/53362/quotes/nls/vicl VICL +1.42% today announced that the company will report financial results for the three months and twelve months ended December 31, 2011, ...
Vical's Allovectin: If Approved, What Kind Of Launch Can Be Expected?
Date: Tue, 31 Jan 2012 15:46:06 GMT
Tags:
Vical's Allovectin: If Approved, What Kind Of Launch Can Be Expected?
Seeking Alpha - Jan 31, 2012
Seeking Alpha - Jan 31, 2012
Following the halting launch of Dendreon's (DNDN) immunotherapy Provenge and the failure of that company to meet its own, initial sales forecasts, one is tempted to ask whether or not Vical Incorporated (VICL) could face similar challenges if and when ...
Vical Presents Case Study on Successful Design of Allovectin Phase 3 Melanoma ... - PharmaLive (press release) (subscription)Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 ...
Date: Mon, 30 Jan 2012 11:30:53 GMT
Tags:
Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 ...
MarketWatch (press release) - Jan 30, 2012
MarketWatch (press release) - Jan 30, 2012
WASHINGTON, Jan 30, 2012 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/zigman/53362/quotes/nls/vicl VICL -1.39% announced today that the company will present a case study of its Allovectin(R) Phase 3 trial at the Phacilitate Cell & Gene ...
Immunotherapy Cancer Trials With Key Data Due In 2012
Date: Wed, 25 Jan 2012 16:44:04 GMT
Tags:
Immunotherapy Cancer Trials With Key Data Due In 2012
Seeking Alpha - Jan 25, 2012
Seeking Alpha - Jan 25, 2012
In man's continuing war against disease he has declared victory against many bacteria, viruses, genetic mutations, injuries and developmental abnormalities.
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements and E
Date: Wed, 08 Feb 2012 11:31:02 GMT
Tags:
Vical Reports 2011 Financial Results and Progress in Key Development Programs
Date: Wed, 08 Feb 2012 11:30:00 GMT
Tags:
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today reported financial results for the year ended December 31, 2011. Vical had cash and investments of approximately $56 million at year-end 2011. In addition, the company ...
Vical Inc.: A $3 Biotech Lottery Ticket I Am Buying Now
Date: Fri, 03 Feb 2012 18:18:05 GMT
Tags:
Vical Announces News Release and Conference Call Schedule for 2011 Financial Results
Date: Thu, 02 Feb 2012 11:30:00 GMT
Tags:
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company will report financial results for the three months and twelve months ended December 31, 2011, before the opening of trading on Wednesday, ...
Vical's Allovectin: If Approved, What Kind Of Launch Can Be Expected?
Date: Tue, 31 Jan 2012 15:45:01 GMT
Tags: